Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.28
+0.41 (6.98%)
At close: Dec 5, 2025, 4:00 PM EST
6.16
-0.12 (-1.91%)
After-hours: Dec 5, 2025, 5:01 PM EST
Eupraxia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Eupraxia Pharmaceuticals stock have an average target of 11.5, with a low estimate of 11 and a high estimate of 12. The average target predicts an increase of 83.12% from the current stock price of 6.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 20, 2025.
Analyst Ratings
The average analyst rating for Eupraxia Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +91.08% | Aug 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $11 | Buy | Initiates | $11 | +75.16% | Jul 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +91.08% | Jun 26, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +43.31% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.84
from -0.76
EPS Next Year
-0.76
from -0.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.56 | -0.53 | ||||
| Avg | -0.84 | -0.76 | ||||
| Low | -1.09 | -0.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.